This site requires Javascript to be enabled on many pages
π½οΈ fluvoxamine maleate,(prescription)
AI Engines For more Details:
Perplexity
Kagi Labs
You
(faverin, fevarin, floxyfral, fluvator, fluxamine, luvox, psyvoxin, revilife, voxamin, voxidep, anwu, apo-fluvoxamine, depromel, dumirox, dumyrox, favoxil, floxyfral junior, fluvoxamina eg, fluvoxamina generis, fluvoxamina sandoz, fluvoxamina teva, fluvoxamine, fluvoxamine actavis, fluvoxamine eg, fluvoxamine maleate amel, fluvoxamine maleate ch, fluvoxamine maleate emec, fluvoxamine maleate ffp, fluvoxamine maleate jg, fluvoxamine maleate kyorin, fluvoxamine maleate np, fluvoxamine maleate pfizer, fluvoxamine maleate synthon, fluvoxamine maleate tck, fluvoxamine maleate towa, fluvoxamine maleate tyk, fluvoxamine maleate yd, fluvoxamine mylan, fluvoxamine nichi-iko, fluvoxamine sandoz, fluvoxamine sawai, fluvoxamine takata, fluvoxamine teva, fluvoxamine tillomed, fluvoxamine wockhardt, fluvoxaminemaleaat apotex, fluvoxaminemaleaat aurobindo, fluvoxaminemaleaat cf, fluvoxaminemaleaat genthon, fluvoxaminemaleaat mylan, fluvoxaminemaleaat pch, fluvoxaminemaleaat sandoz, fluvoxaminemaleaat stada, fluvoxamin-neuraxpharm, fluvoxamin-ratiopharm, fluvoxin, genbou, lote, luvat, luvox cr, maveral, pms-fluvoxamine, relafin, revoxin, riva-fluvox, ruibile, sandoz fluvoxamine, teva-fluvoxamine, voxamine, vuminix)
Impacted of fluvoxamine maleate,(prescription) On Probiotics
Rank
Probiotic
Impact
species
Akkermansia muciniphila
Reduces
species
Bifidobacterium adolescentis
Reduces
species
Bifidobacterium longum
Reduces
species
Escherichia coli
Reduces
species
Lacticaseibacillus paracasei
Reduces
subspecies
Bifidobacterium longum subsp. infantis
Reduces
subspecies
Bifidobacterium longum subsp. longum
Reduces
Bacteria Impacted by fluvoxamine maleate,(prescription)
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species , that would be the genus that is belongs to and the strains in the species.
π§?
Taxonomy
Rank
Effect
Citations
Notation
Clostridioides
genus
Decreases
👪 Source Study
Veillonella
genus
Decreases
👪 Source Study
Akkermansia
genus
Decreases
👪 Source Study
Eggerthella
genus
Decreases
👪 Source Study
Bifidobacterium
genus
Decreases
👪 Source Study
Agathobacter
genus
Decreases
👪 Source Study
Collinsella
genus
Decreases
👪 Source Study
proinflammatory
Dorea
genus
Decreases
👪 Source Study
Odoribacter
genus
Decreases
👪 Source Study
Lachnospira
genus
Decreases
👪 Source Study
Segatella
genus
Decreases
👪 Source Study
Blautia
genus
Decreases
👪 Source Study
Bacteroides
genus
Decreases
👪 Source Study
Roseburia
genus
Decreases
👪 Source Study
Thomasclavelia
genus
Decreases
👪 Source Study
Bilophila
genus
Decreases
👪 Source Study
High Level Cause Brain Fog(Cognitive impairment)
Ruminococcus
genus
Decreases
👪 Source Study
Mediterraneibacter
genus
Decreases
👪 Source Study
Escherichia
genus
Decreases
👪 Source Study
Enterocloster
genus
Decreases
👪 Source Study
Lacrimispora
genus
Decreases
👪 Source Study
Clostridium
genus
Decreases
👪 Source Study
Pathogen
Lacticaseibacillus
genus
Decreases
👪 Source Study
unclassified Robinsoniella
no rank
Decreases
⚗️ Source Study
unclassified Fusobacterium
no rank
Decreases
⚗️ Source Study
unclassified Negativicoccus
no rank
Decreases
⚗️ Source Study
Escherichia coli O80:H26
no rank
Decreases
👶 Source Study
Eggerthellales
order
Decreases
⚗️ Source Study
Escherichia coli O145
serogroup
Decreases
👶 Source Study
Escherichia coli O157
serogroup
Decreases
👶 Source Study
Escherichia coli O26
serogroup
Decreases
👶 Source Study
Escherichia coli O43
serogroup
Decreases
👶 Source Study
Escherichia coli O1:H42
serotype
Decreases
👶 Source Study
Escherichia coli O104:H4
serotype
Decreases
👶 Source Study
Escherichia coli O121:H19
serotype
Decreases
👶 Source Study
Escherichia coli O127:H6
serotype
Decreases
👶 Source Study
Escherichia coli O139:H28
serotype
Decreases
👶 Source Study
Escherichia coli O157:H7
serotype
Decreases
👶 Source Study
bloody diarrhea
Escherichia coli O44:H18
serotype
Decreases
👶 Source Study
Escherichia coli O55:H7
serotype
Decreases
👶 Source Study
Escherichia coli O6:H16
serotype
Decreases
👶 Source Study
Escherichia coli O7:K1
serotype
Decreases
👶 Source Study
Clostridioides difficile
species
Decreases
📓 Source Study
Colitis
Veillonella parvula
species
Decreases
📓 Source Study
Akkermansia muciniphila
species
Decreases
📓 Source Study
Bifidobacterium adolescentis
species
Decreases
📓 Source Study
Eggerthella lenta
species
Decreases
📓 Source Study
Agathobacter rectalis
species
Decreases
📓 Source Study
Collinsella aerofaciens
species
Decreases
📓 Source Study
Bacteroides ovatus
species
Decreases
📓 Source Study
Dorea formicigenerans
species
Decreases
📓 Source Study
Odoribacter splanchnicus
species
Decreases
📓 Source Study
Bifidobacterium longum
species
Decreases
📓 Source Study
Bacteroides xylanisolvens
species
Decreases
📓 Source Study
Lachnospira eligens
species
Decreases
📓 Source Study
Segatella copri
species
Decreases
📓 Source Study
Over 70%ile Indicator of mycotoxin present
Candida albicans
species
Decreases
📓 Source Study
Escherichia coli
species
Decreases
📓 Source Study
Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Pseudomonas aeruginosa
species
Decreases
📓 Source Study
Opportunistic, nosocomial pneumonia and sepsis
Staphylococcus aureus
species
Decreases
📓 Source Study
Skin infections, sinusitis, food poisoning
Blautia obeum
species
Decreases
📓 Source Study
[Ruminococcus] torques
species
Decreases
📓 Source Study
Roseburia hominis
species
Decreases
📓 Source Study
Bacteroides thetaiotaomicron
species
Decreases
📓 Source Study
Thomasclavelia ramosa
species
Decreases
📓 Source Study
Bilophila wadsworthia
species
Decreases
📓 Source Study
Ruminococcus bromii
species
Decreases
📓 Source Study
Anaerofustis stercorihominis
species
Decreases
⚗️ Source Study
Asaccharospora irregularis
species
Decreases
⚗️ Source Study
Escherichia coli
species
Decreases
📓 Source Study
Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Negativicoccus sp. S5-A15
species
Decreases
⚗️ Source Study
Enterocloster bolteae
species
Decreases
📓 Source Study
Paraprevotella clara
species
Decreases
⚗️ Source Study
Slackia sp. NATTS
species
Decreases
⚗️ Source Study
Pseudoflavonifractor capillosus
species
Decreases
⚗️ Source Study
[Collinsella] massiliensis
species
Decreases
⚗️ Source Study
Parvibacter caecicola
species
Decreases
⚗️ Source Study
Bacteroides caccae
species
Decreases
📓 Source Study
Lacrimispora saccharolytica
species
Decreases
📓 Source Study
Clostridium perfringens
species
Decreases
📓 Source Study
Food poisoning, gas gangrene
[Ruminococcus] gnavus
species
Decreases
📓 Source Study
Lacticaseibacillus paracasei
species
Decreases
📓 Source Study
Coriobacterineae
suborder
Decreases
⚗️ Source Study
Bifidobacterium longum subsp. infantis
subspecies
Decreases
👶 Source Study
Bifidobacterium longum subsp. longum
subspecies
Decreases
👶 Source Study
Bifidobacterium longum subsp. suillum
subspecies
Decreases
👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei
subspecies
Decreases
👶 Source Study
Chlamydiae/Verrucomicrobia group
superphylum
Decreases
⚗️ Source Study
Impact of fluvoxamine maleate,(prescription) on Conditions from US National Library of Medicine
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups.
We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition
Positive Impact
Negative Impact
Benefit Ratio Impact
Abdominal Aortic Aneurysm
0.1
0.1
Acne
0.4
-0.4
ADHD
3.4
0.4
7.5
Age-Related Macular Degeneration and Glaucoma
0.5
0.5
Allergic Rhinitis (Hay Fever)
0.3
1.8
-5
Allergies
4.1
3.1
0.32
Allergy to milk products
0.7
0.5
0.4
Alopecia (Hair Loss)
0.9
0.9
Alzheimer's disease
1.9
3.8
-1
Amyotrophic lateral sclerosis (ALS) Motor Neuron
3.1
1.4
1.21
Ankylosing spondylitis
2.8
0.6
3.67
Anorexia Nervosa
1.4
-1.4
Antiphospholipid syndrome (APS)
0.6
0.1
5
Asthma
2.2
2.3
-0.05
Atherosclerosis
0.8
1.3
-0.63
Atrial fibrillation
2.3
1.4
0.64
Autism
6.8
7.1
-0.04
Barrett esophagus cancer
0.5
0.5
benign prostatic hyperplasia
0.1
0.1
Bipolar Disorder
0.5
1.2
-1.4
Brain Trauma
0.7
0.4
0.75
Carcinoma
2.5
1.9
0.32
Celiac Disease
1.3
3.5
-1.69
Cerebral Palsy
1.3
0.7
0.86
Chronic Fatigue Syndrome
3.3
3.1
0.06
Chronic Kidney Disease
1.1
1.5
-0.36
Chronic Lyme
0.4
-0.4
Chronic Obstructive Pulmonary Disease (COPD)
0.5
0.5
0
Chronic Urticaria (Hives)
0.9
1.5
-0.67
Coagulation / Micro clot triggering bacteria
1.4
0.5
1.8
Colorectal Cancer
1.6
1
0.6
Constipation
0.6
0.4
0.5
Coronary artery disease
0.8
0.7
0.14
COVID-19
9.1
9.7
-0.07
Crohn's Disease
4
4.1
-0.02
cystic fibrosis
0.9
0.7
0.29
deep vein thrombosis
1.4
0.3
3.67
Depression
5.5
5.7
-0.04
Dermatomyositis
0.4
-0.4
Eczema
0.6
0.4
0.5
Endometriosis
1.6
1.2
0.33
Eosinophilic Esophagitis
0.5
-0.5
Epilepsy
1.7
2.2
-0.29
Fibromyalgia
1
1.2
-0.2
Functional constipation / chronic idiopathic constipation
3.2
1.8
0.78
gallstone disease (gsd)
1.2
0.5
1.4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus
0.5
0.5
0
Generalized anxiety disorder
0.7
1.2
-0.71
giant cell arteritis
0
0
Graves' disease
0.9
1.1
-0.22
Halitosis
0.7
0.7
Hashimoto's thyroiditis
2.1
0.7
2
Hidradenitis Suppurativa
0.1
0.5
-4
Histamine Issues,Mast Cell Issue, DAO Insufficiency
2.8
0.7
3
hypercholesterolemia (High Cholesterol)
0.3
0.9
-2
hyperglycemia
0.1
2.2
-21
Hyperlipidemia (High Blood Fats)
1.2
0.3
3
hypersomnia
0.3
-0.3
hypertension (High Blood Pressure
1.6
3.3
-1.06
Hypothyroidism
1
-1
Hypoxia
0.7
0.7
IgA nephropathy (IgAN)
2.5
-2.5
Inflammatory Bowel Disease
2
5.9
-1.95
Insomnia
0.4
0.7
-0.75
Intelligence
0
0.6
0
Intracranial aneurysms
0.5
0.3
0.67
Irritable Bowel Syndrome
3.6
3.1
0.16
Liver Cirrhosis
3.4
2.2
0.55
Long COVID
4.3
6.4
-0.49
Low bone mineral density
0.5
-0.5
Lung Cancer
0.2
1.6
-7
ME/CFS with IBS
0.2
1.7
-7.5
ME/CFS without IBS
1.4
1.5
-0.07
Menopause
2.1
2.1
Metabolic Syndrome
4.3
5.3
-0.23
Mood Disorders
8
6.1
0.31
multiple chemical sensitivity [MCS]
0.9
0.2
3.5
Multiple Sclerosis
4.4
2.4
0.83
Multiple system atrophy (MSA)
1.8
0.7
1.57
Neuropathy (all types)
0.7
0.1
6
neuropsychiatric disorders (PANDAS, PANS)
0.7
0.7
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic
1.6
5
-2.13
NonCeliac Gluten Sensitivity
0.4
-0.4
Obesity
5.2
3.3
0.58
obsessive-compulsive disorder
3.7
3.7
0
Osteoarthritis
0.6
0.1
5
Osteoporosis
1.3
1.4
-0.08
pancreatic cancer
0.3
0.3
Parkinson's Disease
3
1.7
0.76
Polycystic ovary syndrome
0.6
1.6
-1.67
Postural orthostatic tachycardia syndrome
0
0.4
0
Premenstrual dysphoric disorder
0.9
0.9
primary biliary cholangitis
0.3
0.3
0
Psoriasis
3.8
1.9
1
rheumatoid arthritis (RA),Spondyloarthritis (SpA)
4.4
2.2
1
Rosacea
0.8
0.2
3
Schizophrenia
5.6
0.9
5.22
scoliosis
0.8
-0.8
Sjögren syndrome
2.7
2.3
0.17
Sleep Apnea
0.7
1
-0.43
Small Intestinal Bacterial Overgrowth (SIBO)
0.8
0.6
0.33
Stress / posttraumatic stress disorder
1.9
2.8
-0.47
Systemic Lupus Erythematosus
1.9
1.5
0.27
Tic Disorder
0.4
1.6
-3
Tourette syndrome
0.5
0.2
1.5
Type 1 Diabetes
1.9
1.3
0.46
Type 2 Diabetes
4.3
3.6
0.19
Ulcerative colitis
1.6
3.9
-1.44
Unhealthy Ageing
2.7
2
0.35
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance.
Special thanks to Oliver Luk, B.Sc. (Biology) from
BiomeSight for spot checking the coding of data from the US National Library of Medicine
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence ) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.